Yellow Fever Clinical Trial
Official title:
Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults
The investigators at Rockefeller University are doing this research to study how the immune
system responds to viruses and other infectious agents by using the yellow fever 17D vaccine
as a model. The YFV-17D vaccine is one of the safest and most effective vaccines known and
has been used to vaccinate humans against yellow fever virus (YFV) infection since the
1930s. By studying how the human immune system responds to the YFV vaccine we hope to learn
more about the normal functioning of the immune system so that it might be possible to
design new, more effective types of vaccines to prevent important infectious diseases.
The reason for doing this research is:
Currently there is very little information about which factors determine the effectiveness
of the initial (primary) immune response to a foreign substance (antigen), such as a virus,
that person may be exposed to. There is also very little known about what determines how
effectively and for how long a person's immune system can react to the same antigen to
prevent another infection. Studies in animals have given us important information about how
the immune systems of other animals behave upon initial or repeated exposure to antigens,but
these topics have not been studied in detail in humans.
The following hypotheses will be tested:
- The magnitude of the initial expansion of T lymphocytes (the "clonal burst") specific
for the infecting virus determines the level at which memory T cell responses are
generated against the specific viral antigen and the duration of the memory T cell
response generated in the body.
- The majority of CD8 T cells generated after immunization are yellow fever specific and
not "bystander activation" of non-specific cells.
n/a
Observational Model: Case-Only, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
| Recruiting |
NCT05568953 -
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
|
Phase 2 | |
| Recruiting |
NCT05447377 -
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
|
Phase 3 | |
| Active, not recruiting |
NCT05011123 -
Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia
|
Phase 2 | |
| Completed |
NCT04267809 -
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection
|
Phase 2 | |
| Completed |
NCT01943305 -
The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans
|
Phase 2 | |
| Completed |
NCT02991495 -
Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)
|
Phase 4 | |
| Not yet recruiting |
NCT03725618 -
Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old
|
Phase 4 | |
| Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
| Completed |
NCT04059471 -
Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine
|
Phase 4 | |
| Completed |
NCT02572518 -
Immunity After Two Doses of Yellow Fever Vaccine
|
N/A | |
| Recruiting |
NCT00694655 -
Human Immune Responses to Yellow Fever Vaccination
|
Phase 4 | |
| Not yet recruiting |
NCT05332197 -
Booster Vaccine for Yellow Fever
|
Phase 3 | |
| Recruiting |
NCT05421611 -
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
|
Phase 3 | |
| Completed |
NCT03116802 -
Yellow Fever Vaccine on Statin/ Non Statin Subjects
|
Phase 2 | |
| Completed |
NCT02743455 -
A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01426243 -
The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.
|
Phase 3 | |
| Completed |
NCT00982137 -
Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)
|
Phase 2 | |
| Active, not recruiting |
NCT04269265 -
The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
|
Phase 1/Phase 2 | |
| Completed |
NCT03870061 -
Evaluation of an Infant Immunization Encouragement Program in Nigeria
|
N/A |